Cutia Therapeutics announced that the New Drug Application for CU-10201 (topical 4% minocycline foam) having been granted priority review designation by the Center for Drug Evaluation of the National Medical Products Administration (the NMPA) of the People's Republic of China (the PRC). The board of directors of the Company announced that the New Drug Application (the "NDA") for CU-10201 was accepted by the NMPA of the PRC. The indication of CU-10201 is for the treatment of non-nodular moderate to severe acne vulgaris in pediatric and adult patients aged nine years and older.

CU-10201 is the first and only topical minocycline approved for acne vulgaris treatment globally and the first topical minocycline to have its NDA accepted by the NMPA of The currently available minocycline products are mostly oral medications. Compared to other major anti-acne antibiotics and conventional oral drugs, topical minocycline foam has lower systemic drug exposure, fewer side effects, a lower rate of drug resistance and likely higher patient compliance. Results of Phase III clinical trial data analysis in the PRC showed that CU-10201 has a significant efficacy and a favorable safety profile in the treatment of acne, with a reduction in the common side effects of oral minocycline.